Application of NKT Cells in Immunotherapy

Author(s): Yasuyuki Ishii, Shinichiro Motohashi, Kanako Shimizu, Toshinori Nakayama, Masaru Taniguchi, Shin-ichiro Fujii.

Journal Name: Current Immunology Reviews

Volume 6 , Issue 2 , 2010

Become EABM
Become Reviewer

Abstract:

Invariant natural killer T (iNKT) cells are a conserved T cell sublineage and an important component of the innate immune system. The invariant T cell antigen receptor (TCR) α chain on iNKT cells interacts with glycolipid presented via CD1d on antigen-presenting cells (APCs), resulting in the production of a variety of cytokines, and thus bridging the innate and adaptive immune systems. In this review, we discuss two strategies of immune modulation that target iNKT cells using either liposomal α-galactosylceramide (α-GalCer) or α-GalCer-loaded APCs. Liposomal α- GalCer generates regulatory iNKT cells, which serve to induce regulatory T cells (Treg) and can be used to diminish immune responses as is seen in autoimmunity and allergic diseases. In contrast, α-GalCer-pulsed APCs generate stimulatory iNKT cells capable of releasing pro-inflammatory cytokines and leading to adaptive immune responses that can be used for treating malignancies. Here, we summarize the modalities used to manipulate the dual nature of iNKT cell function and their tremendous potential in treating both allergic and malignant disease.

Keywords: NKT cells, immunotherapy

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 6
ISSUE: 2
Year: 2010
Page: [109 - 115]
Pages: 7
DOI: 10.2174/157339510791111736
Price: $58

Article Metrics

PDF: 2

Special-new-year-discount